80 related articles for article (PubMed ID: 23499640)
1. Combined standard and novel immunosuppressive substances affect B-lymphocyte function.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Int Immunopharmacol; 2013 Apr; 15(4):718-25. PubMed ID: 23499640
[TBL] [Abstract][Full Text] [Related]
2. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
Matz M; Lehnert M; Lorkowski C; Fabritius K; Unterwalder N; Doueiri S; Weber UA; Mashreghi MF; Neumayer HH; Budde K
Transpl Int; 2012 Oct; 25(10):1106-16. PubMed ID: 22816666
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction.
Amet N; Gacad M; Petrosyan A; Pao A; Jordan SC; Toyoda M
Transpl Immunol; 2010 Aug; 23(4):170-3. PubMed ID: 20609387
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction.
Sharma KG; Radha R; Pao A; Amet N; Baden L; Jordan SC; Toyoda M
Transpl Immunol; 2010 Jul; 23(3):117-20. PubMed ID: 20450974
[TBL] [Abstract][Full Text] [Related]
5. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.
Heidt S; Roelen DL; Eijsink C; van Kooten C; Claas FH; Mulder A
Transplantation; 2008 Nov; 86(9):1292-300. PubMed ID: 19005412
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Martina MN; Ramirez Bajo MJ; Bañon-Maneus E; Moya Rull D; Hierro-Garcia N; Revuelta I; Campistol JM; Rovira J; Diekmann F
Transplant Proc; 2016 Nov; 48(9):3046-3052. PubMed ID: 27932144
[TBL] [Abstract][Full Text] [Related]
7. Renal-sparing regimens employing new agents.
Ruiz R; Klintmalm GB
Curr Opin Organ Transplant; 2012 Dec; 17(6):619-25. PubMed ID: 23111644
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.
Hoogduijn MJ; Crop MJ; Korevaar SS; Peeters AM; Eijken M; Maat LP; Balk AH; Weimar W; Baan CC
Transplantation; 2008 Nov; 86(9):1283-91. PubMed ID: 19005411
[TBL] [Abstract][Full Text] [Related]
9. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone.
Haneda M; Owaki M; Kuzuya T; Iwasaki K; Miwa Y; Kobayashi T
Transplantation; 2014 Feb; 97(4):405-12. PubMed ID: 24445924
[TBL] [Abstract][Full Text] [Related]
11. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Weckbecker G; Pally C; Beerli C; Burkhart C; Wieczorek G; Metzler B; Morris RE; Wagner J; Bruns C
Transpl Int; 2010 May; 23(5):543-52. PubMed ID: 20003043
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.
Heidt S; Roelen DL; Eijsink C; Eikmans M; van Kooten C; Claas FH; Mulder A
Clin Exp Immunol; 2010 Feb; 159(2):199-207. PubMed ID: 19922499
[TBL] [Abstract][Full Text] [Related]
13. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses.
Berry V; Magill A; Yost M; Janosky J; Sindhi R
Cytometry A; 2006 Feb; 69(2):95-103. PubMed ID: 16369935
[TBL] [Abstract][Full Text] [Related]
14. The influence of immunosuppressive drugs on neural stem/progenitor cell fate in vitro.
Skardelly M; Glien A; Groba C; Schlichting N; Kamprad M; Meixensberger J; Milosevic J
Exp Cell Res; 2013 Dec; 319(20):3170-81. PubMed ID: 24001738
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
16. Overview of sotrastaurin clinical pharmacokinetics.
Kovarik JM; Slade A
Ther Drug Monit; 2010 Oct; 32(5):540-3. PubMed ID: 20683390
[TBL] [Abstract][Full Text] [Related]
17. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Matz M; Naik M; Mashreghi MF; Glander P; Neumayer HH; Budde K
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):103-13. PubMed ID: 21142580
[TBL] [Abstract][Full Text] [Related]
19. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
[TBL] [Abstract][Full Text] [Related]
20. Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.
Kovarik JM; Stitah S; Slade A; Vitaliti A; Straube F; Grenet O; Winter S; Sfikas N; Seiberling M
J Clin Pharmacol; 2010 Nov; 50(11):1260-6. PubMed ID: 20386017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
